<DOC>
	<DOCNO>NCT00834405</DOCNO>
	<brief_summary>The objective study compare relative bioavailability leflunomide 20 mg tablet ( manufacture TEVA Pharmaceutical Industries , Ltd. distribute TEVA Pharmaceuticals USA ) ARAVA 20 mg tablet ( Aventis ) healthy , adult , non-smoking subject [ female ( unable become pregnant ) vasectomize male ] non-fasting condition .</brief_summary>
	<brief_title>Leflunomide 20 mg Tablets , Non-Fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>All subject select study nonsmoker least 18 year age . Females must physically unable become pregnant . Males must vasectomize . Weight subject shall 20 % Â± normal height body frame ( Metropolitan Life , 1993 , Height , Weight , Body Chart ) . Each subject shall give general physical examination within 21 day initiation study . Such examination include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . Adequate blood urine sample obtain within 21 day begin first period th eend trial clinical laboratory measurement . Clinical laboratory measurement include follow : 1 . Hematology : hematocrit , hemoglobin , red blood cell count , platelet , white blood cell count ( differential ) . 2 . Clinical chemistry : creatinine , BUN , glucose , SGOT/AST , SGPT/ALT , bilirubin , alkaline phosphatase . 3 . Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . 4 . HIV Screen : prestudy . 5 . HepatitisB , C Screen : prestudy . 6 . Drugs Abuse Screen : prestudy checkin dosing . Subjects select normal . Subjects history chronic alcohol consumption ( past 2 year ) , drug addiction , recent serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test exclude study . Subjects history allergic response cholestyramine exclude study . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure checkin dose . Subjects find urine concentration test drug allow participate . Subjects donate blood and/or plasma least 30 day prior first dose study . Subjects take investigational drug within 30 day prior first dose study allow participate . Female subject pregnant able ( woman child bear potential ) become pregnant study allow participate . All female subject screen pregnancy checkin . Subjects positive inconclusive result withdrawn study . Male subject physically able father child allow participate . Male subject must vasectomize ( least 3 month ) medical verification . Subjects smoke use tobacco form eligible participate study . Three month abstinence require . Subjects unable tolerate multiple venipuncture exclude . Subjects take product contain leflunomide within 180 day dose allow participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>